SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias board investigation into CEO Jensen Huangs acknowledged relationship with a woman reported to have suspected ties to Chinese intelligence is driving attention, with traders debating possible governance, national-security and leadership fallout. Reactions are split between calls to sell over the uncertainty and dip-buying on the view that the allegations do not change Nvidias underlying business.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs Nov. 22 decision on Capricors deramiocel for Duchenne muscular dystrophy, with the application now focused on HOPE-3 upper-limb-function data and a letter from 28 trial investigators urging approval. Many traders expect a favorable decision, while others emphasize the binary risk of a CRL and question whether the data address the FDAs concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios quarterly revenue miss and sequential sales decline have driven a sharp selloff, with traders also criticizing the lack of a conference call and clear commercial guidance. The reaction is divided: bears question Anktivas adoption and execution, while bulls point to the positive BCG-naive trial endpoint and recent label expansion as longer-term offsets.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is drawing attention ahead of its quarterly results, with traders debating whether the recent rebound and heavy short positioning could support further gains or whether weak results or guidance will trigger another selloff. Some view co-founder Dave Pickles return to a technology leadership role as a potential turnaround signal, while skeptics remain concerned about ad-spend growth and management execution.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics BRIUMVI-driven quarterly sales beat and raised full-year outlook are the main focus, with traders also watching for Phase 3 data on a self-administered version. Despite the upbeat report and call, shares fell, prompting debate over sell-the-news pressure and speculation about short selling.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs preliminary third-quarter results and CEO Brad Jacobs bullish conference-call comments are driving attention, with traders encouraged by reported growth and the companys outlook. Bulls see room for a rebound or short-covering, while skeptics remain cautious after the stocks prolonged decline and amid housing-market and interest-rate concerns.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

A quarterly earnings beat and a further increase to Constellations full-year outlook are driving attention, reinforcing traders view that the company can benefit from growing AI data-center demand for reliable nuclear power. Many are bullish on the outlook, though some are frustrated that the shares have not rallied more strongly despite the results.

NRG Energy, Inc. engages in the production, sale, and distribution of energy and energy services. It operates through the following segments: Texas, East, West/Services/Other, Vivint Smart Home, and Corporate Activities. The Texas segment includes all activities related to customer, plant and market operations in Texas, other than Cottonwood. The East segment engages in all activities related to customer, plant and market operations in the East. The West/Services/Other segment is focused on all activities related to customer, plant and market operations in the West and Canada, and activities related to the Cottonwood facility and other investments. The Vivint Smart Home segment is a smart home platform that provides customers with technology, products and services to create a smarter, greener, safer home. The company was founded in 1989 and is headquartered in Houston, TX.

NRG Energy Inc.

NRG is drawing attention after a Q3 earnings beat and an agreement to sell six gas-fired plants, with the proceeds expected to support buybacks and debt reduction. Traders largely welcomed the news, though some noted the sale also gives up the plants future earnings.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics CTX310 Phase 1b data is drawing attention, with traders focusing on reported reductions in ANGPTL3 and triglycerides and the therapys tolerability. The response is cautiously positive, but some question the small patient sample and limited follow-up, while others are frustrated that favorable data has not translated into stronger share-price movement.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Positive Phase 3 ECLIPSE-1 results for Virs hepatitis delta treatment, alongside durable viral suppression in extended SOLSTICE data, are driving attention; traders are bullish on the results but debate whether the news is already priced in and whether Vir should remain independent or attract a buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMCON's Q3 Earnings Surge Y/Y on Wholesale Unit Strength

DIT's fiscal Q3 earnings per share improve year over year as sales climb 12.9%, supported by its wholesale distribution business, while inflationary pressures exert strain on operating costs.

AMCON Downgraded to Underperform Amid Margin Pressure & Rising Costs

DIT's downgrade rating reflects persistent losses, margin compression, rising operating costs, and weak demand trends, highlighting continued pressure on profitability and near-term performance.


AMCON Incurs Q2 Loss, Widens Y/Y Due to Cost Pressures

DIT's fiscal Q2 loss per share widens year over year to $2.34 even as sales rise 16%, aided by strong distribution demand, with higher labor costs weighing on margins.

AMCON Rallies 23% Year to Date: Should You Buy the Stock?

DIT leverages a vast distribution network, strong CPG partnerships, and strategic investments to drive growth, margin expansion, and resilience across both traditional and health-focused retail segments.

AMCON Q1 EPS Soars Y/Y on Strong Wholesale Distribution

DIT's Q1 EPS more than doubles year over year, fueled by robust performance in its wholesale distribution segment and ongoing investment in turnkey retail solutions.

AMCON's 2025 Earnings Decline 87% Y/Y Amid Cost Pressures

DIT's FY25 earnings plunge year over year due to rising operating costs and higher interest expenses, despite modest revenue growth. Strategic acquisitions remain a key focus for management.

The Zacks Analyst Blog Highlights NVIDIA, Chevron, Booking Holdings, EVI Industries and AMCON Distributing

Zacks spotlights NVIDIA, Chevron, Booking, and two microcaps, EVI Industries and AMCON Distributing, with research updates spanning AI, energy, travel, and distribution.

Top Analyst Reports for NVIDIA, Chevron & Booking

NVIDIA rides AI and GPU demand, Chevron leverages Hess and Permian output, while Booking gains from strong travel momentum.

AMCON's Q3 Earnings Slump Y/Y Despite Modest Revenue Growth

DIT posts fiscal Q3 FY25 earnings of $2.13 per share, down YoY as margin pressures and higher SG&A expenses weighed on profits. Sales rose 3% to $739.6 million amid mixed segment results.

AMCON Distributing Co. engages in the distribution of consumer products. It operates through the Wholesale Distribution (Wholesale) and Retail Health Food (Retail) segments. The Wholesale segment refers to the wholesale distribution of consumer products. The Retail segment focuses on the sale of health and natural food products. The company was founded in 1986 and is headquartered in Omaha, NE.

Amcon Distributing Company

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$62.30
Prev Close	$60.78
Open	$63.00
Dividend Yield	0.63%
50-Day Moving Average	$64.47
Beta	0.23
Avg. Volume	1,486.66
PE Ratio	33.12

52-Week High	$95.59
52-Week Low	$59.15
Market Capitalization	$60.81M
EPS (Annual)	$0.615
Price to Book	0.53
Revenue Per Employee	$1.85M

Feed

News

Sentiment

Fundamentals

Info

DIT Fundamentals